Small Cap Spike: Semi Stock AEHR Up +40% in 2026 Post-Earnings

Aehr Test Systems reported Q2 FY2026 revenue of $9.9M, down 27% YoY and below the $11.5M consensus, while adjusted EPS loss narrowed to $0.04 versus an expected $0.08 and adjusted net loss was $1.3M (prior-year net income ~$0.7M). Management said backlog rose to $18.3M, received >$5.5M of Sonoma AI-system orders, and guided combined revenue of $25M–$30M for the next two quarters with bookings of $60M–$80M (FY2026 revenue guided to $46M–$51M), positioning AI-driven demand to drive FY2027 growth. The update underpins upside given the nascent $8B–$10B test-and-burn-in AI market opportunity, but shares already trade at >12x implied FY2027 sales and downside remains from weak SiC/EV demand and execution risk.

Analysis

Market structure: AEHR is transitioning from a SiC/EV niche into AI test-and-burn-in, so primary winners are leading-edge AI chipmakers and small-cap specialized test-equipment vendors that can capture burn-in demand; losers include SiC-focused supply-chain constituents (lower SiC test volumes) and broad EV-test equipment vendors if demand remains weak. With bookings of $60–80M for the next two quarters vs. FY2026 revenue guide $46–51M, demand appears front-loaded but concentrated—if Sonoma systems scale, AEHR could gain share in a $8–15B TAM for AI test, giving it transient pricing power in a narrow segment.

Risk assessment: Key tail risks are customer concentration (few “leading-edge AI companies”), order cancellations/delays, and ramp execution (manufacturing/service capacity), any of which could erase upside; liquidity risk exists if equity dilution is needed to fund growth. Timewise, expect equity volatility immediate-days on sentiment, booking-to-revenue conversion over 2–8 quarters, and durable market-share moves in 12–36 months; catalysts include quarterly booking conversion, large customer references, and FY2027 revenue evidence.

Trade implications: Tactical trades favor small, risk-defined exposure to AEHR—size positions at 1–2% of portfolio, use option spreads to cap downside, and consider a relative long AEHR / short WOLF (WOLFSPEED) pair to express AI-upside vs. continued SiC softness. If you prefer delta-neutral, sell calendar call spreads against near-term strength to monetize implied vol while holding long-dated LEAP call spreads (12–18 months) to capture FY2027 revenue conversion; tighten stops if bookings < $60M.

Contrarian angles: Consensus may underweight conversion risk—bookings do not equal revenue and could be service-heavy or non-recurring; conversely the market may underprice AEHR’s niche advantage if multiple AI customers scale purchases in 2027–28. Historical parallels include specialized test-tool vendors that surged during one-cycle node transitions but later faced margin pressure when competition and commoditization arrived; rapid scale could therefore compress margins or force capital raises, surprising bullish holders.

Key Decisions for Investors

• Establish a size-constrained long in AEHR equal to 1–2% of liquid portfolio capital (ticker: AEHR); set a hard stop-loss at -35% and a target of +100% over 12–24 months conditional on bookings converting into FY2027 revenue above $60M.
• Execute a defined-risk option play: buy 12–18 month AEHR LEAP call spread (buy Jan 2027/Jan 2028 ITM/near-ATM call, sell a higher strike to fund cost) sized to equal 1% portfolio exposure; exit if quarterly bookings < $60M or if management guidance is revised downward.
• Run a pairs trade: go long AEHR (0.5–1% portfolio) and short Wolfspeed (WOLF) sized to neutralize beta to the semiconductor sector, expressing a tilt toward AI test upside while hedging continued SiC/EV weakness; reassess after two quarterly reports.
• Reduce incremental new exposure to pure SiC names (e.g., WOLF) by 20% and rotate that capital into AI-capex beneficiaries (test equipment suppliers and burn-in services) over the next 60–90 days, prioritizing names with stable service revenue.
• Close or cut AEHR exposure immediately if next quarterly bookings fall below the $60M floor, or if management reduces FY2026 revenue guidance below $46M, as those are binary triggers that materially increase downside risk.